WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...
Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...
As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback